ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: L01 • ACR Convergence 2024

    Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases

    Matthew Martin1, Erik Wilker1, Diana Gikunju1, Usha Narayanan1, Unnati Pandya1, Vijetha Prakash1, Ashley Edwards1, Sameer Kawatkar1, Tenghui Chen1, Ragunath Chandran1, Sai Sunder1, Sumathi Biradar1, Joerg Distler2, Alexandra Joseph1, Stephanos Ioannidis1 and Bhavatarini Vangamudi1, 1Exo Therapeutics, Cambridge, MA, 2Exo Therapeutics, Düsseldorf, Germany

    Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…
  • Abstract Number: L03 • ACR Convergence 2024

    CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus

    Kyleigh Brimmer1, Olivia Antao1, Daniel Mayer1, Gina Sanchez1, Rebecca Francis1, Htay Htay Kyi2, Mary Salim2, Boyan Xia2, Eugenio Capitle2 and Jason Weinstein1, 1Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, 2Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
  • Abstract Number: L10 • ACR Convergence 2024

    Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study

    John Tesser1, Joshua June2, Pendleton Wickersham3, Jane Box4, Guillermo Valenzuela5, Angela Crowley6, Nikila Kumar7, Norman Gaylis8, Gordan Lam9, David Ridley10, Gineth Paola Pinto-Patarroyo11 and David Chernoff12, 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2Great Lakes Center of Rheumatology, Lansing, MI, 3Arthritis Associates PA, San Antonio, TX, 4DJL Clinical Research, PLLC, Charlotte, NC, 5Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, 6Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, 7Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, 8Arthritis & Rheumatic Disease Specialties, Aventura, FL, 9Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, 10St. Paul Rheumatology, Eagan, MN, 11Annapolis Rheumatology, Fairfax, VA, 12SetPoint Medical, Sausalito, CA

    Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
  • Abstract Number: L12 • ACR Convergence 2024

    A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity

    Chunli Mei1, Xin Guan1, Bin Wu2, Mengjiao Li1, Xiaojing Liu1, Xi Chen1, You Song1, Weiwei Wang1, Cheng Wang1, Huiling Mei1, Xiaoru Duan1, Lijuan Jiang1, Wenlin Qiu1, Likai Yu1, Yuhong Liu1, Xing Zhao3, Xuanfan Zhong3, Shengjie Xue3, Wuzhong Shen3, Ying Tan3, Guojian Yu3, Guiyun Tu3, Hanyang Chen3, Amy Sun3, Xiaoqiang Yan3, Anbing Huang1, Rong Du1 and Qiubai Li1, 1Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2Department of Rheumatology and Immunology of the First People’s Hospital of Jingzhou, Jingzhou, China, 3ITabMed Ltd. Changchun, Shanghai, China

    Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…
  • Abstract Number: L19 • ACR Convergence 2024

    Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials

    Alexei Grom1, Uwe Ullman2, Adnan Mahmood3, Josefin Blomkvist3, Brian Jamieson4 and Fabrizio De Benedetti5, 1Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, 2Sobi, Basel, Switzerland, 3Sobi, Stockholm, Sweden, 4Sobi, Inc., Morrisville, NC, 5Bambino Gesu Children's Hospital, Rome, Italy

    Background/Purpose: MAS is a life-threatening complication of Still’s disease, characterized by interferon-gamma (IFNg)-driven macrophage activation and systemic hyperinflammation. Emapalumab, an anti-IFNg antibody, binds free and…
  • Abstract Number: 0015 • ACR Convergence 2024

    Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution

    Ana Merino Vico1, Yosta Vegting1, Aldo Jongejan1, Jan Piet van Hamburg1, Perry moerland1, Sander Tas2 and Marc Hilhorst1, 1Amsterdam UMC, Amsterdam, Netherlands, 2Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel autoimmune vasculitis, associated with severe lung and kidney impairment. B cells are crucial in AAV…
  • Abstract Number: 0146 • ACR Convergence 2024

    Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions

    Bashar Tanous1, SRIKAR SAMA2, Nidaa Rasheed3 and Candice Reyes4, 1UCSF Fresno, Fresno, 2University of California San Francisco Fresno, Fresno, CA, 3UCSF Fresno, Fresno, CA, 4VACCHCS, Fresno, CA

    Background/Purpose: Biologic response modifiers (BRMs), also known as "biologics," have become essential tools in treating various chronic inflammatory conditions. However, the immunosuppression caused by these agents…
  • Abstract Number: 0293 • ACR Convergence 2024

    Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database

    Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY

    Background/Purpose: Autoimmune diseases are known to be associated with an increased risk of many types of cancers. This study investigates the association between different types…
  • Abstract Number: 0379 • ACR Convergence 2024

    Effectiveness and Safety of Baricitinib for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis in Children

    Athimalaipet Ramanan1, Catherine Guly2, Gabriele Simonini3, Stuart Keller4, Priyanka Sen4, Thorsten Holzkaemper4 and PIERRE QUARTIER5, 1Bristol Royal Hosp for Children, Bristol, United Kingdom, 2University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, 3Meyer Children’s Hospital IRCCS; University of Florence, Florence, Toscana, Italy, 4Eli Lilly and Company, Indianapolis, IN, 5Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France

    Background/Purpose: Baricitinib could target multiple cytokine pathways associated with juvenile idiopathic arthritis associated uveitis (JIA-U) and antinuclear antibody (ANA)-positive uveitis, providing a novel therapeutic approach.…
  • Abstract Number: 0607 • ACR Convergence 2024

    Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial

    Andrea Fava1, Michelle Petri2, David Jayne3, Patrick G Gavin4, Eszter Csomor5, Philip Z Brohawn4, Daniel Muthas6, Adam Platt5, Catharina Lindholm7 and Nicola Ferrari5, 1Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Timonium, MD, 3University of Cambridge, Cambridge, United Kingdom, 4BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 5BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 7BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: An elevated type I interferon gene signature (IFNGS) is associated with more active disease in patients with LN.1 Anifrolumab, a type I interferon receptor…
  • Abstract Number: 0780 • ACR Convergence 2024

    Deep B Cell Tissue Depletion Following Anti-CD19 CART Cells Therapy

    Carlo Tur1, Markus Eckstein2, Velden Joachim3, Christina Bergmann4, Janina Auth1, Laura Bucci1, Giulia Corte5, Melanie Hagen1, Andreas Wirsching1, Ricardo Grieshaber-Bouyer1, Petra Reis1, Nicolai Kittan1, Jochen Wacker1, Simon Rauber1, Aleix Rigau6, Andreas Ramming1, Maria Antonietta D'Agostino7, Arndt Hartmann8, Fabian Müller9, Andreas MAckensen10, Aline Bozec1, Georg Schett11 and Maria Gabriella Raimondo1, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 2Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 3Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 4Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 5Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, 6Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 7Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, 8Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 9Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, 10Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 11Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has proved potential for achieving long-term drug-free remission in patients with autoimmune diseases (AIDs).  Its effectiveness likely…
  • Abstract Number: 0889 • ACR Convergence 2024

    Unraveling the Progression of Sjögren’s Disease at the Cellular and Histological Level Using Single-cell and Spatial Transcriptomics

    Tomás Gomes1, Matilde Bandeira2, Rui do Amaral Vieira1, Bianca Correia1, Sofia Barreira3, Pedro Gaspar4, Rita Cruz-Machado5, Beatriz Filipe1, Pedro Ávila-Ribeiro1, Filipa Ribeiro1, Bruno Vidal1, Beatriz Val1, Filipa Costa6, Ana Teodósio Chícharo7, Augusto Silva1, Manuel Silvério-Antonio1, João Forjaz Lacerda1, João Eurico Fonseca1, Dolores López Presa8, Nikita Khmelinskii1, Saumya Kumar9, Luis Graca1 and Vasco C. Romão10, 1Instituto de Medicina Molecular (iMM Lisboa), Lisboa, Portugal, 2Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, 3Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisbon, Portugal, 4Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Povoa de Santa Iria, Portugal, 5Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisboa, Portugal, 6Rheumatology Department, Unidade Local de Saúde de Santa Maria. Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal, 7Unidade Local de Saúde do Algarve, Hospital de Faro, Faro, Portugal, Faro, Portugal, 8Pathology Department, Unidade Local de Saúde de Santa Maria, Lisbon Academic Medical Centre, Lisboa, Portugal, 9TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany, Hannover, Germany, 10Rheumatology Department, ULS Santa Maria & Rheumatology Research Unit, Instituto Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal

    Background/Purpose: Sjögren’s Disease (SjD) is a systemic autoimmune disease that primarily targets salivary and lacrimal glands, causing tissue deterioration and loss of function. Disease progression…
  • Abstract Number: 0967 • ACR Convergence 2024

    Transcriptional Heterogeneity of Immune Cells in the Esophagus of Systemic Sclerosis Patients: A Comparison of Upper and Lower Esophageal Regions

    Hadijat Makinde1, Miranda Gurra1, Salina Dominguez2, Matthew Dapas2, Tyler Therron2, Kathleen Aren3, Marie-Pier Tetreault2, Monique Hinchcliff4, Deborah Winter5 and Harris Perlman1, 1Northwestern University, Chicago, IL, 2Northwestern University, Chicago, 3Northwestern University Division of Rheumatology, Chicago, IL, 4Yale School of Medicine, Westport, CT, 5Northwestern University, Skokie, IL

    Background/Purpose: Systemic sclerosis (SSc) is characterized by an initial inflammatory phase followed by fibrosis. Esophageal dysfunction in SSc is associated with gastroesophageal reflux, leading to…
  • Abstract Number: 1121 • ACR Convergence 2024

    A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AMG 329, a Monoclonal Antibody, in Conventional and Plasmacytoid Dendritic Cell-Mediated Rheumatic Diseases

    Alan Kivitz1, Stanley Cohen2, Annie Lau-Kilby3, Yajing Sun3, Jiayin Huang3, Atasi Jana3, Susie Kim3, Yanping Wu3, Quinnie Yang3 and Lin Zhao3, 1Altoona Center for Clinical Research, Duncansville, PA, 2Metroplex Clinical Research Center, dallas, TX, 3Amgen Inc., Thousand Oaks, CA

    Background/Purpose: AMG 329 (formerly HZN-1116), a human monoclonal antibody (mAb), binds to soluble and membrane-bound human feline McDonough sarcoma (FMS)-like tyrosine kinase 3 receptor ligand…
  • Abstract Number: 1406 • ACR Convergence 2024

    Development and Functional Characterization of Salivary Gland Organoids to Investigate Sjögren’s Disease

    Negaar Goudarzi1, Loïc Meudec2, Juliette Pascaud2, Fanny Jaulin3, Quentin Pascal4, Thierry Lazure5, Sacha E Silva Saffar2, Xavier Mariette6 and Gaetane Nocturne6, 1University Paris-Saclay, Le Kremlin Bicêtre, France, 2University Paris Saclay, Le Kremlin Bicetre, France, 3Institut Gustave Roussy, Villejuif, France, 4CEA, Fontenay aux roses, France, 5APHP. Université Paris-Saclay, Hôpital Bicêtre, Anatomie et cytologie pathologiques, Paris, France, 6Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease that manifests as glandular dryness and systemic symptoms. Salivary gland epithelial cells (SGEC) are pivotal in…
  • 1
  • 2
  • 3
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology